AFIRE Study Algorithm (AF + Stable CAD) Calculator

Clinical calculation support · Verify results before clinical use

Clinical decision support

Review whether the stable coronary disease setting resembles the population studied in AFIRE. This is a decision aid, not an automated prescription.

AFStable CAD
Recorded for clinical context; age alone does not determine eligibility for the stable-CAD antithrombotic strategy.
Coronary disease / revascularization status Choose the single best description. CAD not requiring revascularization is a separate AFIRE pathway and does not require waiting one year from diagnosis.
Currently taking an antiplatelet agent? Aspirin or a P2Y12 inhibitor (e.g., clopidogrel).
High bleeding risk? Consider ARC-HBR criteria and overall clinical assessment. This input does not replace formal bleeding-risk assessment.

How to interpret this tool

AFIRE studied patients with atrial fibrillation and stable coronary artery disease who had undergone PCI or CABG at least one year earlier, or had angiographically confirmed CAD not requiring revascularization. The trial compared rivaroxaban monotherapy with rivaroxaban plus a single antiplatelet agent.

The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline recommends OAC monotherapy over OAC plus a single antiplatelet agent for chronic coronary disease beyond one year after revascularization, or CAD not requiring revascularization, when there is no history of stent thrombosis, to reduce major bleeding.

Before changing therapy

  • Confirm that oral anticoagulation is indicated for AF and that the selected agent and dose are appropriate for renal function, age, interactions, and local guidance.
  • Check for recent ACS/PCI, prior stent thrombosis, complex coronary anatomy, recurrent ischemia, or another clear indication for antiplatelet therapy.
  • Review bleeding risk and patient-specific ischemic risk with the treating clinician. Do not discontinue prescribed medication solely on the basis of this calculator.

References

Yasuda S, et al. AFIRE Investigators. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381:1103–1113. DOI: 10.1056/NEJMoa1904143.
Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1–e156. DOI: 10.1161/CIR.0000000000001193.
Clinical disclaimer: This educational decision aid is not a validated risk score, does not replace guideline review or clinician judgment, and does not prescribe a specific anticoagulant or dose. AFIRE was conducted in Japan; local drug dosing and practice recommendations may differ. Patients with mechanical heart valves, moderate-to-severe rheumatic mitral stenosis, recent ACS/PCI, prior stent thrombosis, or other special indications require individualized assessment.